Private label Zantac 75 marketable December 1998 under Glaxo/Novopharm ruling.
This article was originally published in The Tan Sheet
Executive Summary
PRIVATE LABEL OTC RANITIDINE WILL BE MARKETABLE IN DECEMBER 1998 as a result of Novapharm's victory in the Form 1 ranitidine patent case with Glaxo Wellcome. Raleigh, N.C. federal court Judge Terrence Boyle ruled July 5 that Novopharm has established that it is possible to manufacture Form 1 ranitidine without infringing Glaxo's patent for Form 2 of the anti-ulcer agent Zantac.